Dry eye disease
Conditions
Interventions
Experimental Group 4:Warm Compress (Once Weekly) + Meibomian Gland Expression (Once Weekly)
Experimental Group 6:Warm Compress (Once Daily) + 0.1% Sodium Hyaluronate Eye Drop (Four Times Daily)
Experimental Group 1:Warm Compress (Once Daily)
Experimental Group 2:Warm Compress (Twice Daily)
Experimental Group 3:Meibomian Gland Warm Vapor Therapy (Once Weekly) + Meibomian Gland Expression (Once Weekly)
Experimental Group 5:0.1% Sodium Hyaluronate Eye Drops (Four Times Daily)
Sponsors
The second affiliated hospital of Zhejiang University school of medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Age between 18 and 65 years; 2.Eligible for the diagnosis of dry eye disease, meeting either of the following two conditions: (1) FBUT =1 subjective dry eye symptom (such as dryness, foreign body sensation, burning, fatigue, or blurred vision), along with OSDI >= 13 or SPEED >= 6; (2). 5 s = 1 subjective symptom AND OSDI >= 13 or SPEED >= 6, and positive corneal/conjunctival fluorescein staining; 3.Presence of mild-to-moderate Meibomian Gland Dysfunction (MGD), meeting at least one of the following: (1). Meibomian gland dropout score of 1–2 (0 = normal; 1 = loss 2/3); (2). Meibomian gland expressibility score of 1–2 (0 = secretions expressed from all 5 glands; 1 = expressed from 3–4 glands; 2 = expressed from 1–2 glands; 3 = no gland expresses secretions); (3). Meibomian gland secretion quality score of 1–2 (0 = clear, transparent liquid; 1 = cloudy liquid; 2 = cloudy with particulate matter; 3 = thick, toothpaste-like secretions); 4.Able and willing to sign written informed consent and comply with study procedures and follow-up schedule.
Exclusion criteria
Exclusion criteria: 1.Complete obstruction or severe atrophy of the meibomian glands; 2.Active ocular surface infection or other severe ocular diseases; 3.History of ocular surgery within the past 6 months, including eyelid surgery, LASIK, cataract surgery, etc; 4.Wearing contact lenses; 5.Use of other dry eye treatments within the past month (e.g., corticosteroids, cyclosporine); 6.Presence of severe systemic diseases that may affect tear secretion or the ocular surface (e.g., Sjögren’s syndrome, uncontrolled diabetes); 7.Pregnancy or breastfeeding; 8.Known allergy or hypersensitivity to any components of the study products (e.g., warm compress patch materials, sodium hyaluronate eye drops); 9.Cognitive impairment, psychiatric disorders, or any condition that may prevent proper understanding of informed consent or compliance with study procedures; 10.Any other condition deemed inappropriate for study participation by the investigators, such as an anticipated inability to complete follow-ups or planned relocation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fluorescein Break-up Time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Meibomian Gland Orifice Grade;Meibum Quality Score;Tear Meniscus Height;Meibomian Gland Dropout Score;Non-Invasive Break-up Time;Meibomian Gland Expressibility Score;Corneal Fluorescein Staining Score; | — |
Countries
China
Contacts
Public ContactJin Xiuming
The second affiliated hospital of Zhejiang University school of medicine
Outcome results
None listed